News|Articles|February 3, 2026 (Updated: February 13, 2026)
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle
Author(s)CoverMyMeds
This case study leverages IQVIA data and analytics to explore how one pharmaceutical brand navigated mature lifecycle stages in a competitive class, implementing seamless prior auth strategies with CoverMyMeds where a 22 percentage point claim approval rate lift was observed, on average, helping mitigate decreasing access.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Novo Nordisk Announces Significant Price Drops for Popular GLP-1 Medications
2
Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN
3
Pharma Manufacturing Roundup: AbbVie Invests $380 Million to Expand API Manufacturing, Bora Pharmaceuticals and GSK Enters Five Year Manufacturing Agreement
4
Merck’s Oncology Spin-Out: Organizational Design as Patent Cliff Strategy
5